Browsing by Author "Yin, Ji-Ye"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair
    (American Association for Cancer Research, 2011) Yin, Ji-Ye; Shen, Jie; Dong, Zi-Zheng; Huang, Qiong; Zhong, Mei-Zuo; Feng, De-Yun; Zhou, Hong-Hao; Zhang, Jian-Ting; Liu, Zhao-Qian; Pharmacology and Toxicology, School of Medicine
    Purpose: The purpose of this study is to test the hypothesis that eIF3a may regulate the expression of DNA repair proteins which, in turn, affects response of lung cancer patients to treatments by DNA-damaging anticancer drugs. Experimental design: Immunohistochemistry was used to determine the expression of eIF3a in 211 human lung cancer tissues followed by association analysis of eIF3a expression with patient's response to platinum-based chemotherapy. Ectopic overexpression and RNA interference knockdown of eIF3a were carried out in NIH3T3 and H1299 cell lines, respectively, to determine the effect of altered eIF3a expression on cellular response to cisplatin, doxorubicine, etoposide (VP-16), vincristine, and vinblastine by using MTT assay. The DNA repair capacity of these cells was evaluated by using host-cell reactivation assay. Real-time reverse transcriptase PCR and Western Blot analyses were carried out to determine the effect of eIF3a on the DNA repair genes by using cells with altered eIF3a expression. Results: eIF3a expression associates with response of lung cancer patients to platinum-based chemotherapy. eIF3a knockdown or overexpression, respectively, increased and decreased the cellular resistance to cisplatin and anthrocycline anticancer drugs, DNA repair activity, and expression of DNA repair proteins. Conclusions: eIF3a plays an important role in regulating the expression of DNA repair proteins which, in turn, contributes to cellular response to DNA-damaging anticancer drugs and patients' response to platinum-based chemotherapy.
  • Thumbnail Image
    Item
    eIF3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response
    (SpringerLink, 2017) Yin, Ji-Ye; Dong, Zizheng; Zhang, Jian-Ting; Pharmacology and Toxicology, School of Medicine
    Translation initiation is the rate-limiting step of protein synthesis and highly regulated. Eukaryotic initiation factor 3 (eIF3) is the largest and most complex initiation factor consisting of 13 putative subunits. A growing number of studies suggest that eIF3 and its subunits may represent a new group of proto- oncogenes and associates with prognosis. They regulate translation of a subset of mRNAs involved in many cellular processes including proliferation, apoptosis, DNA repair, and cell cycle. Therefore, unveiling the mechanisms of eIF3 action in tumorigenesis may help identify attractive targets for cancer therapy. Here, we describe a series of methods used in the study of eIF3 function in regulating protein synthesis, tumorigenesis, and cellular response to therapeutic treatments.
  • Thumbnail Image
    Item
    eIF3a: A new anticancer drug target in the eIF family
    (Elsevier, 2018-01) Yin, Ji-Ye; Zhang, Jian-Ting; Zhang, Wei; Zhou, Hong-Hao; Liu, Zhao-Qian; Pharmacology and Toxicology, School of Medicine
    eIF3a is the largest subunit of eIF3, which is a key player in all steps of translation initiation. During the past years, eIF3a is recognized as a proto-oncogene, which is an important discovery in this field. It is widely reported to be correlated with cancer occurrence, metastasis, prognosis, and therapeutic response. Recently, the mechanisms of eIF3a action in the carcinogenesis are unveiled gradually. A number of cellular, physiological, and pathological processes involving eIF3a are identified. Most importantly, it is emerging as a new potential drug target in the eIF family, and some small molecule inhibitors are being developed. Thus, we perform a critical review of recent advances in understanding eIF3a physiological and pathological functions, with specific focus on its role in cancer and anticancer drug targets.